Mesoblast (MSB) FDA Announcement summary

Introduction and purpose

• Ryoncil (remestemcel-L) received FDA approval as the first mesenchymal stromal cell (MSC) therapy in the U.S. for any indication, for children aged two months and older with steroid-refractory acute graft-versus-host disease (GVHD).

• Emphasis on the company's commitment to addressing unmet medical needs in the GVHD community and plans to expand indications.

Details of approval or decision

• Ryoncil is the only FDA-approved therapy for pediatric steroid-refractory acute GVHD, including adolescents and teenagers.

• Approval based on a single-arm, multi-center Phase 3 trial showing a 70% overall response rate by Day 28.

• The product will be launched in the coming weeks, focusing on top U.S. transplant centers and hospitals.

Impact on industry and stakeholders

• Sets a benchmark for regulatory expectations and clinical standards for cell therapies.

• Provides a life-saving option for children with SR-aGvHD, a condition with high mortality and limited treatments.

• Demonstrates a viable commercialization path for regenerative medicine and may attract strategic partnerships for larger indications.

• Company holds over 1,000 patents, ensuring commercial protection through at least 2041 in major markets.

• Approval expected to catalyze further interest from larger pharmaceutical and biotech companies.